Kevin White
Executive Director - Venture Fund Boehringer Ingelheim
Kevin White is an Investment Manager with the Boehringer Ingelheim Venture Fund, focusing on strategic investments and new company creation across North America. Prior to joining BIVF, he held leadership roles in immunology discovery at AbbVie and spent a decade in the respiratory therapeutic area at Novartis; he completed postdoctoral studies at Harvard Medical School and earned his PhD at the University of Glasgow
Seminars
- Pharma’s reflections on recent in vivo CAR-T and TCE deals, what data was valuable when clinical data was minimal?
- Overlapping and diverging advantages of TCEs to in vivo CAR-T, including depth and durability of response.
- Debating clinical-adjacent innovations in delivery across viral vectors and LNPs and their application in immunology versus oncology
Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience, within this track.
Starting with a short investor panel introducing investor interests and moving into an organised networking session.
Mirroring the Pharma Introduction Tables, select the investors that best align with your organisation’s stage and objectives, and join their networking table for 30-minutes. Share business cards or ask a followup question from the panel with your target investor to tick off another key connection at the conference.
